Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Daily Practice

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Post-marketing surveillance to gather information regarding the tolerance and efficacy of Spiriva® 18 micrograms in patients with COPD under conditions of daily practice.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Bromides; Tiotropium Bromide

Criteria

Inclusion Criteria:

• Men and women aged at least 40 years with the symptoms of Chronic Obstructive Pulmonary Disease

Exclusion Criteria:

• Patients with the general and specific contraindications listed in the Patient Information Leaflet and the Basic Product Information